Abrysvo is a vaccine for protecting against lower respiratory tract disease (LRTD; diseases of the lungs such as bronchitis or pneumonia) caused by respiratory syncytial virus (RSV) in people aged 18 years and older. It is also used in pregnant women to protect their infants against LRTD from birth until they are 6 months of age. Abrysvo contains versions of two proteins found on the surface of the virus called RSV subgroup A stabilised prefusion F and RSV subgroup B stabilised prefusion F.
Therapeutic Indication
Abrysvo is indicated for: * Passive protection against lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants from birth through 6 months of age following maternal immunisation during pregnancy. * Active immunisation of individuals 18 years of age and older for the prevention of lower respiratory tract disease caused by RSV. The use of this vaccine should be in accordance with official recommendations.
Therapeutic Area (MeSH)
ATC Code
J07BX05
ATC Item
N/A
Pharmacotherapeutic Group
Other viral vaccines
Active Substance (Summary)
INN / Common Names
EMA Name
Abrysvo
Medicine Name
Abrysvo
Aliases
N/ANo risk management plan link.
